Single Photon Emission Computed Tomography (SPECT) combined with X-ray computed tomography (CT) provides high-sensitivity functional imaging with precise anatomical localization for radionuclide drug conjugates (RDCs). Alfa Cytology provides a full suite of customizable, end‑to‑end SPECT/CT services, from radiolabeling optimization and dose formulation to longitudinal imaging and quantitative analysis, ensuring support for RDC candidates at any preclinical stage.
SPECT/CT is a hybrid molecular imaging modality widely employed in preclinical RDC development to non‑invasively track the biodistribution, target engagement, and pharmacokinetics of radiolabeled therapeutics. By overlaying the functional signal from gamma‑emitting isotopes with the high‑resolution anatomical framework provided by CT, SPECT/CT enables longitudinal monitoring of the same animal, reducing inter‑subject variability and accelerating go/no‑go decisions in drug development. This synergy allows for the precise three-dimensional localization of RDCs within specific organs or tumor microenvironments, facilitating a deep understanding of drug behavior in live subjects.
Fig.1 Radiation dosimetry considerations in 177Lu‑PSMA‑617 therapy. (Jackson, P., et al., 2022)
The fundamental mechanism of SPECT involves the detection of single gamma-photon emissions from decaying radioisotopes, which are captured by rotating gamma cameras equipped with lead collimators to determine the direction of the photons. Advanced reconstruction algorithms then transform these signals into volumetric images representing the concentration of the tracer. When superimposed with CT data acquired by measuring X-ray attenuation through various tissues, the resulting hybrid image offers a comprehensive view of both the physiological activity and the exact physical coordinates of the RDC.
The integration of SPECT and CT overcomes the limitations of standalone nuclear imaging by providing essential anatomical context and superior quantitative accuracy. This dual-modality platform is particularly valued for its ability to resolve complex biological processes in vivo with high spatial and temporal resolution.
High Sensitivity for Picomolar Targets
The platform detects trace amounts of radiolabeled RDCs even at extremely low concentrations. This high-sensitivity molecular detection enables precise characterization of early-phase biodistribution and tumor-targeting kinetics, ensuring that subtle binding events at low-abundance receptors are accurately captured.
Superior Depth Penetration and Signal Integrity
Unlike optical modalities, gamma photons are not significantly attenuated by biological tissues. This ensures that signals from deep-seated organs or internal tumor sites are captured without loss, allowing for comprehensive whole-body distribution mapping and consistent data quality across all subjects.
Quantitative Capability and Accuracy
By utilizing high-resolution CT data for sophisticated attenuation and scatter correction, the system provides absolute radioactivity quantification. This allows for the precise calculation of metrics such as %ID/g or SUV, transforming qualitative images into rigorous, statistically significant datasets for regulatory review.
Longitudinal Study Design
Non-invasive protocols permit repeated scanning of the same animal over several days or weeks. This longitudinal capability tracks RDC accumulation and clearance pathways within the same subject, significantly reducing inter-subject variability and the total number of animals required for research.
Utilizing high-performance hardware and sophisticated image processing pipelines, Alfa Cytology's services provide robust datasets that define the pharmacokinetic and pharmacodynamic profiles of novel RDCs. By leveraging expertise in isotope chemistry and small-animal imaging, the platform delivers actionable insights into tumor targeting and off-target accumulation. We offer tailored imaging protocols, rigorous quality control, and expert data analysis are provided to meet specific RDC program needs.
A broad range of gamma‑emitting radionuclides can be routinely used to label RDCs for SPECT/CT imaging, thanks to established radiochemistry platforms, energy‑specific collimator sets, and validated acquisition/reconstruction protocols. The table below lists commonly supported radionuclides, their key properties, and typical RDC imaging uses.
| Isotope | Half‑life | Typical Applications |
|---|---|---|
| ⁹⁹ᵐTc | 6.0 h | Diagnostic scouting, perfusion studies, and labeling of targeted peptide probes. |
| ¹¹¹In | 2.8 d | Long‑term biodistribution, antibody‑RDC tracking. |
| ¹²³I | 13.2 h | Neuroendocrine receptor targeting and small-molecule RDC pharmacokinetics. |
| ¹²⁵I | 59.4 d | Antibody‑ or peptide‑based RDCs; high‑resolution small‑animal SPECT/CT imaging. |
| ¹³¹I | 8.0 d | Theranostic evaluation of targeted iodine therapies via medium-energy SPECT. |
| ¹⁷⁷Lu | 6.7 d | Standard theranostic imaging for dosimetry and post-therapy monitoring. |
| ⁴⁷Sc | 3.35 d | Emerging theranostic isotope paired with ¹⁷⁷Lu-like therapy for single-agent imaging. |
| ¹⁸⁸Re | 17.0 h | Evaluation of high-energy therapeutic RDCs for bone metastases and solid tumors. |
| ¹⁵³Sm | 1.93 d | Bone‑targeting RDC distribution and research in radiopharmaceutical pain palliation. |
| ¹⁶¹Tb | 6.89 d | Low-energy SPECT for novel theranostics focusing on micro-metastatic lesions. |
| ²⁰¹Tl | 3.0 d | Assessment of tumor viability and multi-tracer studies of myocardial perfusion. |
| … | … | … |
Dynamic SPECT/CT Imaging
Captures rapid physiological processes through continuous acquisition immediately post-injection. This approach resolves first-pass kinetics, vascular permeability, and early renal clearance, providing high-resolution temporal data essential for defining the initial distribution phase and metabolic rate of novel RDC candidates.
Static Whole-Body SPECT/CT
Provides high-sensitivity snapshots at discrete intervals (e.g., 4h, 24h, 72h) to evaluate steady-state biodistribution. By utilizing the same subject across all time points, this method minimizes biological variance and offers a non-invasive correlation to traditional ex vivo tissue counting and organ uptake studies.
Longitudinal Tumor & Efficacy Studies
Monitors therapeutic response and target retention by performing repeated scans over days or weeks. Quantitative analysis of signal intensity and tumor volume allows researchers to directly correlate RDC accumulation with growth inhibition, providing robust imaging endpoints for assessing overall treatment efficacy.
Pharmacokinetics (PK) & Biodistribution Mapping
Integrates quantitative voxel data into compartmental models to extract critical parameters such as influx rates and volume of distribution. This service transforms raw activity counts into comprehensive time-activity curves, characterizing systemic transit and specific organ-level clearance pathways with high precision.
Dosimetry & Safety Assessment
Utilizes time-integrated activity data derived from serial scans to estimate absorbed radiation doses via advanced computational modeling. These evaluations are vital for predicting target-to-background ratios and establishing the therapeutic window by identifying potential dose-limiting toxicities and safety margins in healthy tissues.
Alfa Cytology offers a complete, expert‑driven SPECT/CT imaging service for RDC preclinical development, covering everything from dynamic whole‑body distribution and multi‑isotope competition studies to longitudinal tumor monitoring and absorbed dose estimation. Every study is supported by rigorous quality control, quantitative reconstruction, and transparent data reporting. To discuss specific project needs or request a customized imaging protocol, please contact us.
References
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.